Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.95 USD | +1.24% | -0.19% | -27.51% |
May. 23 | Transcript : Progyny, Inc. - Shareholder/Analyst Call | |
May. 22 | Progyny Gets Board Approval for $100 Million Share Repurchase Program; Stock Rises After Hours | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 37.37 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Managed Healthcare
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-27.51% | 2.57B | C+ | ||
-5.91% | 456B | B- | ||
+14.19% | 125B | A- | ||
+15.08% | 97.9B | B- | ||
-21.78% | 43.15B | A- | ||
-3.53% | 38.2B | B- | ||
-8.59% | 1.51B | B- | ||
+15.53% | 546M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PGNY Stock
- Ratings Progyny, Inc.